MPC Therapeutics SA

We develop novel small molecules that modulate mitochondrial function and rejuvenate cells. Our lead product, MITO-66, is a reagent that improves the performance of CAR T cell therapies against cancer. Used during the ex vivo manufacturing process, MITO-66 triggers an epigenetic reprogramming and generate T cells that can persist, self-renew and provide durable stemness. MITO-66 is currently being tested by more than 10 CAR T manufacturers. Our goal is to start a clinical phase in 2024 with at least one of these players. Beyond T cells, our small molecules have been shown to trigger the proliferation of stem cells in a variety of tissues (skin, intestine, neurons) which offers exciting perspectives in other indications.